BEIJING, April 30, 2026 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company") (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), a leading AI company with strong Internet foundation, today announced that it will hold its annual general meeting of shareholders (the "AGM") at Baidu Campus, No. 10, Shangdi 10th Street, Haidian District, Beijing 100085, People's Republic of China on June 5, 2026 at 9:00 a.m. (Beijing/Hong Kong time).

No proposal will be submitted for shareholder approval at the AGM.

The board of Directors of the Company has fixed the close of business on May 18, 2026, Hong Kong time, as the record date (the "Shares Record Date") of Class A ordinary shares with a par value of US$0.000000625 each (the "Class A Ordinary Shares") and Class B ordinary shares with a par value of US$0.000000625 each (the "Class B Ordinary Shares"). Holders of record of the Company's Class A Ordinary Shares and Class B Ordinary Shares as of the Shares Record Date are entitled to receive notice of and attend the AGM and any adjourned meeting thereof.

The notice of the AGM is available on the Company's website at https://ir.baidu.com.

The Company has filed its annual report on Form 20-F, including its audited financial statements, for the year ended December 31, 2025 (the "Form 20-F"), with the U.S. Securities and Exchange Commission. The Form 20-F can be accessed on the Company's website at https://ir.baidu.com, as well as on the SEC's website at http://www.sec.gov.

The Company has also published an annual report (the "Hong Kong Annual Report") pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("HKEx"). The Hong Kong Annual Report contains substantially the same information as set forth in the Form 20-F and can be accessed on the Company's investor relations website at https://ir.baidu.com as well as the HKEx's website at http://www.hkexnews.hk.

About Baidu

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under "BIDU" and HKEX under "9888". One Baidu ADS represents eight Class A ordinary shares.

BERGEN, Norway, April 30, 2026 /PRNewswire/ -- Xtep, a leading global performance running brand, officially unveiled PB Master – a new flagship initiative under the X‑RUN Program – with a high‑energy debut at the 2026 Bergen City Marathon. The launch immediately struck a chord with local runners, drawing strong turnout and active participation.

On race day, Tage Morken Augustson, wearing Xtep racing gear, took the championship with a time of 2:34:06. Runners wearing Xtep's flagship running shoes praised the shoes' outstanding propulsion and stability over the full marathon distance.

About PB Master Program

PB Master is a dedicated runner support program created by X‑RUN for marathoners worldwide. Centered on runner passion and competitive performance needs, the program provides free racing shoes and technical apparel. It also offers cash rewards for runners who achieve new personal bests (PBs), inspiring everyday committed runners to experience Xtep's professional performance products.

As part of the X‑RUN Program ecosystem, PB Master joins the Global Elite Program, 10KM Time Trial, and X‑Run Camp to offer runners more platforms to challenge limits and build strength on the road.

After its successful launch in Bergen, PB Master will expand to more than 16 marathons across Southeast Asia, Central Asia, Russia & CIS, Europe, and the Middle East. Runners may follow Xtep's official Instagram @xtepofficial for race schedules, registration, and latest updates.

How to Join PB Master

• Scan the QR code on race posters (released two months before each event)
• Submit registration proof for Xtep‑selected races
• Upload your personal best result from the past 12 months (same category)

Program Benefits

• 50 selected runners per race receive a free Xtep gear pack: 1 technical T‑shirt + 1 pair of performance running shoes (must be worn during the race)
• First 20 runners who set a new PB earn a $60 cash reward
• Participants must share two videos: gear unboxing and in‑race recap, with links submitted for verification

Notes: Sizes are subject to availability. Team registration QR codes will be released two months prior to each race.

For inquiries, contact: [email protected] 

Xtep Performance Running Footwear

Backing PB Master is Xtep's high‑performance Champion Edition running shoe series, engineered for all paces and levels:

• 160X Series: Elite racing shoes. 160X 7.0 supports 3:30–4:00 marathoners with carbon‑plate propulsion at ~4:30/km pace; 160X 7.0 PRO is built for sub‑3:30 and sub‑3:00 runners.
• 260X Series: Advanced training & racing for sub‑4:00 marathoners, covering 3:00/km to 7:00/km paces.
• 360X Series: Entry‑level daily training shoe with a softer, milder carbon plate for everyday comfort and support.

Upcoming Global Stops

Following Bergen, PB Master will continue its tour in key markets:

• Jakarta Marathon, Indonesia – June 13–14, 2026
• Alamein Cairo Runners, Egypt – July 24, 2026

Runners worldwide are invited to join Xtep PB Master, chase new personal bests, and run farther, faster, and stronger.

Anthropic is in talks with investors for a new round of financing, targeting a valuation of US$900 billion, surpassing OpenAI's US$852 billion valuation in a funding round in late March, CNBC quoted sources as saying.

A few days ago, Anthropic released the Claude Mythos Preview, a model equipped with advanced cybersecurity features and available only to select companies, which sent shockwaves through Wall Street.

Mythos is also one of the reasons Anthropic is seeking new funding, as Anthropic needs sufficient capital to purchase the computing power required to run Mythos.
~

AASTOCKS Financial News
Website: www.aastocks.com

Revenue up 10% Year-on-Year
Daily Mass GGR rose 19% Year-on-Year Reached New High

HONG KONG, April 30, 2026 /PRNewswire/ -- MGM China Holdings Limited ("MGM China" or the "Company"; SEHK Stock Code: 2282) today announced the selected unaudited financial data of the Company and its subsidiaries (the "Group") for the three months ended March 31, 2026 (the "Period").

The Group is pleased to see Macau's average daily visitor arrival in the first quarter up 14% year-on-year to 124,599. Gross gaming revenue (GGR) in Macau rose by 14% year-on-year, with daily GGR reaching a post-pandemic high.

• MGM China saw net revenue up 10% year-on-year to HK$8.8 billion. Daily total GGR grew 13% year-on-year, and daily mass GGR (including slot) surged 19% to historical high.

• Adjusted EBITDA grew 4% year-on-year to HK$2.5 billion. The Group saw VIP hold percentage at 2.5%, compared with 3.5% a year ago. Adjusted EBITDA margin for the Period was 28.0% (25Q1: 29.6%).

• By property, MGM COTAI saw revenue up by 10% year-on-year to HK$5.3 billion. Adjusted EBITDA rose 11% to HK$1.6 billion. Adjusted EBITDA margin gained 20 basis points to 30.5%. VIP hold was 3.4% (25Q1: 3.4%).

• MGM MACAU's revenue was up by 9% year-on-year to HK$3.4 billion. Adjusted EBITDA was HK$832 million (25Q1: HK$903 million). VIP hold was 0.6% (25Q1: 4.2%).

• MGM China saw overall GGR marketshare at 15.4% (25Q1: 15.7%). Estimated Mass (including slot) marketshare grew to 16.2%, (25Q1: 15.8%) and VIP marketshare was 10.2% (25Q1: 15.4%).

• Average occupancy was 93.9% for the Period (25Q1: 93.3%).

• MGM China maintained a healthy financial position. As of March 31, 2026, the Group had total liquidity of approximately HK$25 billion, comprised of bank balances and cash and available undrawn credit facilities.

During the Period, MGM China is again recognized with seven Five-Star Awards from Forbes Travel Guide, reaffirming our unwavering commitment to delivering exceptional guest experiences. This year marks a milestone as MGM MACAU earns its 11th consecutive Five-Star rating, while Tria Spa at both MGM MACAU and MGM COTAI receives the accolade for the seventh consecutive year. In addition, Emerald Tower, Skylofts, Five Foot Road at MGM COTAI, and Imperial Court at MGM MACAU, have each been honored with Five-Star recognition for the fifth consecutive year, underscoring MGM's consistent excellence across accommodation, wellness, and dining.

In February, the Group celebrated the opening of the renowned Singapore dining brand Chatterbox Café at MGM MACAU, its first Macau outpost. With a legacy spanning over five decades, Chatterbox is rooted in classic Singaporean cuisine and has grown into a highly recognized culinary brand across Asia, distinguished by blending authentic flavors and contemporary culinary skills. By bringing this emblematic international brand to Macau, MGM not only expands the city's dining diversity for both locals and visitors, but also further elevates Macau's global culinary landscapes, strengthening the city's reputation as a UNESCO Creative City of Gastronomy.

The Group also continues to invest in its competitive advantages to support future growth. MGM COTAI has recently completed the suite conversion and refurbishment of premium gaming area. The Prime Wellness Suites include approximately 60 keys and opened before the May Golden Week.

Kenneth Feng, Chief Executive Officer of MGM China said: "Our outstanding performance demonstrates our deep understanding of customers and focus on what they truly want. It also honors our team's commitment and effort in improving products and service levels as well as crafting compelling experiences for our guests."

The Group plans to renovate the hotel suites at MGM MACAU, to ensure the offerings stay fresh and along with evolving customer taste, further strengthening the complementary positioning of our properties – with MGM MACAU as the leading property on the Peninsula and MGM COTAI as the preferred destination for premium customers.

"We are committed to bringing more unique and integrated experiences to our customers, to develop Macau into a global and diversified tourist destination through our concession commitments," said Kenneth Feng.

About MGM China Holdings Limited
MGM China Holdings Limited (HKEx: 2282) is a leading developer, owner and operator of gaming and lodging resorts in the Greater China region. We are the holding company of MGM Grand Paradise, SA which holds one of the six gaming concessions to run casino games in Macau. MGM Grand Paradise, SA owns and operates MGM MACAU, the award-winning premium integrated resort located on the Macau Peninsula and MGM COTAI, a contemporary luxury integrated resort in Cotai, which opened in early 2018 and more than doubles our presence in Macau. 

MGM China is majority owned by MGM Resorts International (NYSE: MGM) one of the world's leading global hospitality companies, operating a portfolio of destination resort brands including Bellagio, ARIA, MGM Grand, Mandalay Bay and Park MGM. For more information about MGM Resorts International, visit the Company's website at www.mgmresorts.com.

收益按年上升10%
每日中場博彩毛收入按年增長19%  創新高

香港2026年4月30日 /美通社/ -- 美高梅中國控股有限公司（「美高梅中國」或「本公司」；香港聯交所股份代號：2282）今天公佈本公司及其附屬公司（「本集團」）截至2026年3月31日止三個月（「本期間」）的未經審核節選財務數據。

本集團欣然見證澳門於第一季度訪澳旅客人數每日平均達124,599人次，按年上升14%。澳門博彩毛收入亦按年增長14%，每日中場博彩毛收入創疫情後新高。

• 美高梅中國淨收入按年增長10%至88億港元。整體日均博彩毛收入按年上升13%，日均中場博彩總收入（包括角子機）按年躍升19%，創歷史新高。

• 經調整 EBITDA按年增長 4%至25億港元。本集團貴賓賭枱贏率為2.5%，去年同期為3.5%。經調整EBITDA利潤率為28.0%（2025年第一季：29.6%）。

• 美獅美高梅收益按年上升10%至53億港元。經調整EBITDA為16億港幣，按年增長11%，經調整EBITDA利潤率則提升20個基點至30.5%。貴賓賭枱贏率為3.4%（2025年第一季：3.4%）。

• 澳門美高梅收益按年上升9%至34億港元。經調整EBITDA為 8.32億港元（2025年第一季：9.03億港元）。貴賓賭枱贏率為0.6% （2025年第一季：4.2%）。

• 美高梅中國整體博彩毛收入市場份額為15.4% （2025年第一季：15.7%）。估計中場博彩毛收入（包括角子機）市場份額上升至16.2%（2025年第一季：15.8%），貴賓博彩毛收入市場份額為佔10.2% （2025年第一季：15.4%）。

• 本期間酒店平均入住率為93.9%（2025年第一季：93.3%）。

• 美高梅中國保持穩健財務狀況。於2026年3月31日，集團總流動資金為約250億港元，包括銀行結餘及現金、以及循環信貸融通的可供動用借款額。

於本期間，美高梅中國再度榮膺《福布斯旅遊指南》七項五星殊榮，充分體現團隊堅定為賓客營造非凡體驗的承諾。今年，澳門美高梅更迎來第十一年蟬聯五星評級的里程碑，而澳門美高梅與美獅美高梅的水療品牌—「禪潺」，亦連續七年獲得五星殊榮。此外，美獅美高梅的「美藝」、「天樂閣」及「蜀道」餐廳，以及澳門美高梅的「金殿堂」餐廳，均連續第五年獲頒五星評級，印證美高梅持續於住宿、康體及餐飲服務方面精益求精。

本集團於2月慶祝新加坡著名餐飲品牌 「話匣子」（Chatterbox Café）於澳門美高梅正式開幕，為該品牌首次進駐澳門。「話匣子」擁有超過五十年的悠久歷史，糅合新加坡地道風味與現代烹飪技巧而享譽盛名。美高梅是次促成這個具代表性的國際品牌落戶澳門，不僅為本地饕客與訪澳旅客提供更多元的餐飲選擇，更進一步提升澳門的國際餐飲格局，助力鞏固「創意城市美食之都」的美譽。

本集團持續投放資源，強化自身競爭優勢，以推動未來增長。美獅美高梅已完成套房升級及高端博彩區翻新工程。全新天瑞套房共設約60間套房，並於五月黃金周前正式投入服務。

美高梅中國首席執行官馮小峰表示：「美高梅中國的卓越表現，體現我們深明顧客所需，同時亦彰顯團隊致力優化產品與服務，努力不懈為顧客打造極具吸引力的體驗。」

集團計劃翻新澳門美高梅的套房，以確保產品具備競爭力，切合客戶不斷演變的品味與喜好，進一步鞏固旗下酒店的互補定位，澳門美高梅為半島領先的酒店，而美獅美高梅銳意成為高端客戶的首選目的地。

馮小峰續說：「我們致力為賓客帶來更多獨特且多元的綜合體驗，並透過履行特許經營承諾，推動澳門發展成為全球多元化的旅遊目的地。」

關於美高梅中國控股有限公司
美高梅中國控股有限公司(香港交易所股份代號 :  2282)，為大中華地區領先的娛樂場博彩度假酒店發展商、擁有者和運營商之一，是美高梅金殿超濠股份有限公司的控股公司，為六家持有澳門經營博彩業務特許權之企業之一。美高梅金殿超濠現時擁有及經營兩家酒店，一為位於澳門半島、屢獲殊榮的豪華綜合度假酒店 - 澳門美高梅；另一為 2018年初開業、位於路氹城的現代豪華綜合度假酒店 - 美獅美高梅，使我們在澳門的版圖擴大逾一倍。

美高梅中國控股有限公司主要由美高梅國際酒店集團 (MGM Resorts International) 擁有(紐約證券交易所代號：MGM)。美高梅國際酒店集團是世界領先的全球酒店及餐飲款待公司，其轄下的度假酒店項目包括百樂宮大酒店 (Bellagio) 、亞利亞(ARIA)、美高梅大酒店 (MGM Grand)、曼德拉灣大酒店(Mandalay Bay)及Park MGM。有關美高梅國際酒店集團的詳情，請瀏覽www.mgmresorts.com。

With four officials dissenting, the most dissenting votes in more than 33 years, the Federal Reserve kept interest rates unchanged as expected.

The three major US stock indices softened on Wednesday. The DJIA ended down 280 points or 0.6% at 48,861, marking a five-day losing streak. The S&P 500 dropped 2 points to close at 7,135. The Nasdaq rose 9 points, closing at 24,673.

Amazon (AMZN.US) maintained a 1% gain for the day, while Microsoft (MSFT.US) fell 1%. Seagate (STX.US) surged 11% amid an aggressive rally in memory and storage hardware stocks.
~



AAStocks Financial News
Web Site: www.aastocks.com

In the first 26 days of April, China's retail sales in the new energy passenger car market reached 614,000 units, down 11% YoY and 6% MoM, according to data released by the China Passenger Car Association (CPCA). Total retail sales YTD amounted to 2.523 million units, down 19% YoY.
~

AASTOCKS Financial News
Website: www.aastocks.com

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increasing the R&D intensity, the Company maintained a positive growth trend in profit. Net profit attributable to shareholders of the list company after deducting extraordinary gain or loss was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, increased by 13.87% YoY. Net cash flows generated from operating activities was RMB 1,149 million, up 8.8% YoY.

In the first quarter of 2026, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma firmly continued to advance its innovation transformation, promoted the deep synergy between innovation and R&D and global operations, and further enhanced the foundation for high-quality development. Driven by the continuous increase in R&D investment, the Company's transformation of innovative achievements continues to materialize. During the reporting period, the NDA for 4 Innovative Drugs were accepted by the NMPA or the U.S. FDA, and 14 clinical trials for Innovative Drugs (calculated by approval) were approved by domestic and overseas regulatory authorities, covering core therapeutic areas such as oncology. In the Pharma R&D Annual Review 2026 white paper released by the world-known consulting firm Citeline, Fosun Pharma ranked among the global top 20, gained international professional recognition for its innovative R&D strength and pipeline quality.

Deepening Core Technology Platforms to Consolidate Advantages in Oncology and Other Fields

Fosun Pharma has established an open-ended R&D system that combines in-house R&D, co-development, licensing, fund incubation, and industrial investment, also focused on strengthening core technology platforms such as antibodies/ADC, small molecules, and cell therapy, continuously consolidating its innovation moat in core therapeutic areas including oncology.

In the field of antibody/ADC technology platform, Shanghai Henlius, a subsidiary of Fosun Pharma, has steadily advanced the approvals and clinical progress of several self-developed biological drugs. Notably, denosumab injection (HLX14) secured approval in Canada in March 2026, covering all indications of the reference product approved locally, achieving a global commercialization breakthrough in areas such as osteoporosis, bone metastasis from tumors, and giant cell tumor of bone. The NDA for bevacizumab injection (HLX04) was accepted in the U.S., marking a new milestone in the Company's international registration capabilities for biosimilars. HLX43, an antibody-drug conjugate targeting PD-L1, is expected to create synergy with HLX07 or serplulimab injection for the treatment of advanced colorectal cancer and other solid tumors. HLX3901, a tetraspecific antibody of DLL3×DLL3×CD3×CD28, received approval for clinical trial, demonstrating significant potential in refractory solid tumors through multi-target synergistic activation of immune cells.

In the field of small molecule innovative drug platform, in January 2026, the NDA for foritinib succinate capsules (SAF-189), Fosun Pharma's Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment of lung cancer. In February 2026, the NDA for the self-developed MEK 1/2 inhibitor luvometinib tablets (Trade name in Chinese mainland: Fu Mai Ning⁾ for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) have been accepted and granted in the priority review by the NMPA. This marks a critical step toward full-age coverage following its approval for pediatric and adolescent NF1 patients in May 2025, also brings new hope to a large number of adult NF1 patients in China who lack effective drug treatments. Additionally, the NDA for methoxyetomidate hydrochloride injection (ET-26), a Class 1 innovative drug self-developed by the subsidiary Avanc Pharma for anesthesia induction and short-term surgical anesthesia, was also accepted.

In the field of prospective layout of early-stage pipeline, several new molecules have been approved for the clinical trials: FXB0871, a PD-1-targeted IL-2 fusion protein, was approved for clinical trials in locally advanced or metastatic solid tumors. Based on the ATTENUKINE™ platform, FXB0871 is expected to achieve high efficacy and low toxicity. FXS0683, a next-generation Bcl-2 inhibitor, was approved for Phase I clinical trials in hematological malignancies. Innovative molecule including HLX97 (a KAT6A/B small molecule inhibitor) and HLX3901 (tetra specific antibody of DLL3×DLL3×CD3×CD28) were approved for clinical trials, widely covering refractory solid tumors such as breast cancer and small cell lung cancer. Meanwhile, HLX22 (anti-HER2 monoclonal antibody) entered phase II clinical trials for the first-line treatment of HER2-positive recurrent or metastatic breast cancer in combination with HLX87. HLX43 (PD-L1 ADC) in combination with HLX07 or serplulimab injection, and HLX701 (CD47 fusion protein), among others, have entered Phase I clinical trials, further enhancing the Company's layout in the fields of tumor immunology and targeted therapy.

Expanding Global Commercialization Network and Enhancing Academic Influence

During the reporting period, Fosun Pharma's global registration and commercialization network continued to expand. The overseas registration of products like denosumab and bevacizumab progressed steadily. The Company reached deep collaborations with global partners such as Eisai and Abbott to accelerate the market coverage of innovative products in Japan, Asia-Pacific, Middle East, Africa, and Eastern Europe.

In the academic field, several innovation achievements were presented at top international conferences such as AACR and ASCO. The Phase III study data of luvometinib tablets for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) was selected for a rapid oral abstract session at 2026 ASCO, the study results will be released for the first time during the meeting. At the 2026 AACR Annual Meeting, Shanghai Henlius, a Fosun Pharma's subsidiary, presented preclinical data for the novel trispecific T-cell engager HLX3902 and the tetraspecific antibody HLX3901, demonstrating best-in-class treatment potential, building a solid foundation for the future clinical development.

AI Embracement: Driving Digital Transformation via FoSTRAID

Fosun Pharma continues to deepen its digitalization and AI strategic layout, and systematically advances the platformisation, engineering and scaled implementation of AI capabilities focusing on core aspects such as new drug R&D, clinical research, products and services, and operation management. On this basis, the fully AI- embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data science) was further defined and steadily advanced. By integrating resources, a digital-intelligence architecture that promotes synergistic development across "foundation — platform — data — agent — scenario — mechanism" has been established.

The self-developed PharmAID^® Pharmaceutical Intelligence Platform deeply applies large language models, fine-tuned with professional medical corpora and R&D data. It integrates full-cycle of decision-making tools including competitor analysis, clinical competitive performance evaluation, NDA approval prediction, and peak sales estimation, comprehensively applied in key scenarios such as target discovery, molecular optimization, clinical writing, intelligence retrieval, and literature interpretation, providing systematic and data-driven support for drug R&D decision-making.

Looking ahead, Fosun Pharma will continue to adhere to the dual drivers of innovation and globalization, deepen its core technology platforms, promote the implementation of AI strategy and accelerate the transformation of its pipeline and global market access. The Company remains committed to providing high-quality healthcare products and services to patients worldwide, striving to become a leading global healthcare innovation integrator.

- END -

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/

香港2026年4月28日 /美通社/ -- 復星國際有限公司（香港聯交所股份代號：00656，簡稱「復星國際」）及其附屬公司（統稱「復星」或「集團」）發佈2025年環境、社會及管治（簡稱ESG）報告。面對愈發嚴峻的全球氣候變化挑戰，復星對標香港聯交所《主板上市規則》附錄C2「環境、社會及管治報告守則」D部分（「新氣候規定」），並參考氣候變化相關財務信息披露工作組（TCFD）建議框架及《國際財務報告準則S2號—氣候相關披露》（「IFRS S2」）發佈了第四份氣候信息披露報告。

作為植根中國、佈局全球的產業集團，復星始終將可持續發展置於戰略核心，以務實行動回應時代與社會的期望。復星的可持續發展戰略為「創造影響力」（Create IMPACT），緊扣六大長期戰略方向，即：I: Innovation-driven 創新驅動、M: Mindful Operation 責任運營、P: People and Partner Oriented 以人為本、A: Advanced Governance精益治理、C: Climate and Planet Positive 綠色發展、T: Transparency透明真實。

積極推動全球可持續發展，ESG評級屢獲佳績

復星以「創新」與「全球化」為引擎，積極深化ESG與商業融合，加速低碳轉型、拓展責任投資、強化社會實踐，以「全球資源嫁接中國能力」，在超過40個國家和地區負責任運營，為全球可持續發展貢獻復星力量。作為負責任的全球公民，復星於2014年正式加入聯合國全球契約組織，全力支持聯合國全球契約組織在人權、勞工、環境及反腐敗等領域的十項原則，並將這些原則與「創造影響力」的可持續發展戰略及行動準則深度融合。

過去一年，儘管全球環境、社會與經濟充滿不確定性，復星仍堅定履行對可持續發展的長期承諾，並收獲佳績。根據最新MSCI 5.0版標準的ESG評級，復星國際MSCI ESG評級榮升AAA，恒生可持續發展評級保持AA-，入選標普全球《可持續發展年鑑2026》並連續位列中國最佳1%；富時羅素ESG評分升至4.2分，並連續第五次入選FTSE4Good成份股。

積極應對氣候變化，推動低碳轉型

面對氣候變化與低碳轉型的趨勢，復星積極響應國家「雙碳」目標，推動碳中和與節能減排，於2021年向社會做出承諾：「力爭於2028年實現碳達峰、2050年實現碳中和」，通過制訂氣候變化緩解和適應策略，支持《巴黎協定》的1.5℃控溫目標。復星更在2050碳中和承諾的基礎上，提出以2024年為基準年，至2034年範圍1和範圍2的溫室氣體排放強度下降20%的中期目標，這是復星對運營排放的嚴格約束，也彰顯集團推動低碳轉型的決心與行動力。

在綠色金融方面，復星持續運用可持續發展掛鈎融資工具拓展低碳與可持續轉型資金來源。2025年，集團完成到期銀團貸款再融資，並籌組首批規模達6.75億美元等值的三年期可持續發展掛鈎銀團貸款，延續綠鞋機制吸引新增銀行參與，最終於2025年9月簽約時總規模增至9.1億美元等值，創公司近五年離岸銀團貸款規模新高，並刷新2025年以來離岸市場民營企業同類貸款規模紀錄，體現資本市場對復星國際可持續發展與融資結構優化方向的認可。

集團積極推動成員企業開展氣候行動。集團在上海的主要辦公場所—上海地標性建築外灘金融中心（BFC）在規劃初期即引入並遵循被譽為綠色建築界的「奧斯卡」LEED 標準，建造初期獲 LEED 金級認證，並於 2022 年以全球最高分榮獲 LEED 鉑金級認證。2025 年，Club Med旗下97%符合條件的度假村通過審核並獲得全球可持續旅遊權威標準—Green Globe 認證；三亞亞特蘭蒂斯、太倉阿爾卑斯國際度假區及麗江地中海國際度假區獲 LEED 金級認證等，展現復星在綠色建築與可持續旅遊領域的持續努力與成果。

復星葡萄牙保險Fidelidade在COP29宣佈成立氣候變化影響研究中心（ICCC），推動氣候風險管理創新，並在COP30展示階段性成果。成立一年以來，ICCC在森林火災風險建模方面取得突破，並開發洪水災害模型工具和預警系統，助力防災政策與社區韌性提升。同期，公司推出創新投資項目—葡萄牙森林基金（Florestas de Portugal），通過森林管理、碳捕捉和土地治理探索兼顧經濟回報與環境效益的可持續投資模式，成為保險業以金融力量參與生物多樣性保護與氣候行動的典範。

2025年，復星繼續以低碳技術打造豫園燈會，踐行碳中和理念，讓東方生活美學與可持續理念交融。依託復星全球平台，豫園燈會已走出國門，先後落地法國巴黎、越南河內、泰國曼谷，成為中外文化交流的重要載體，持續向世界講述「中國故事」，傳遞可持續生活的美好願景。

創新驅動，為患者帶來治癒希望

復星堅持創新驅動，秉持為更多患者帶來治癒希望的初心。旗下健康產業圍繞未被滿足的臨床需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。

其中，漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤、食管鱗癌等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。

此外，復星醫藥持續助力非洲社區健康發展。截至2025年12月底，復星醫藥自主研發的注射用青蒿琥酯累計救治全球超8,800萬重症瘧疾患者，已向全球累計供應超過4.4億支注射用青蒿琥酯。

商業向善，積極回饋社會

「商業向善」是復星不變的承諾。為更好地推動企業社會責任的履行和實施，復星基金會於2012年成立，在全球應急馳援、鄉村振興、健康、教育、文化藝術及青少年發展等領域不懈努力，創造社會價值。復星基金會持續推進鄉村醫生項目，自2017年啓動的鄉村醫生項目，已覆蓋16個省、市、自治區的78個項目縣，累計守護2.5萬名鄉村醫生，惠及300萬戶農村家庭，並將「AI村醫助手」帶入基層，提升醫療服務覆蓋面與效率。

自上而下的ESG改進長效機制，ESG表現與董事會績效掛鈎

復星建立了自上而下的ESG提升長效機制，將ESG管理績效納入執行董事績效評估體系，亦將ESG管理績效考核制度覆蓋範圍延伸至本集團CEO及各業務集團負責人。復星在董事會下設立ESG董事委員會，協助董事會指導及監察集團發展及落實ESG工作。在管理及決策層面，復星在管理層設立ESG決策委員會，對ESG戰略落地提供決策支持。在執行層面，集團亦成立了ESG管理委員會及ESG工作小組，確保設立合適及有效的ESG風險管理及內部監控系統，全面落實復星國際的ESG策略及相關行動。

展望未來，復星將繼續聚焦主業、堅持創新和全球化發展。同時，公司將持續關注全球可持續發展趨勢，不斷完善ESG管理體系，積極響應國家戰略，保障信息安全，落實「雙碳」目標，參與公益慈善，保障員工權益，借助復星全球產業生態的資源與優勢，在可持續發展領域創造更大影響力，持續為世界創造美好。

了解復星ESG的更多詳情，請參閱復星國際2025年ESG報告：
香港聯交所披露易網站（https://www.hkexnews.hk/index_c.htm）
或本公司ESG網站（https://www.fosun.com/esg/）
復星國際2025年氣候信息披露報告電子版本發佈於本公司ESG網站：
（https://www.fosun.com/esg/）

關於復星
復星創立於1992年，經過逾30年發展，已成為一家創新驅動的全球家庭消費產業集團。秉持讓全球家庭生活更幸福的使命，復星致力於服務全球家庭客戶，戰略聚焦健康、快樂、富足的幸福生態系統。2007年復星國際在香港聯交所主板上市（股份代號：00656.HK），截至2025年12月31日，公司總資產達人民幣7,162億元，最新MSCI ESG評級為AAA。

NINGDE, China, April 28, 2026 /PRNewswire/ -- On April 27, CATL and HyperStrong signed a strategic cooperation agreement on sodium-ion batteries for energy storage in Ningde, Fujian. The two parties announced a three-year partnership covering 60GWh of sodium-ion battery supply, marking a significant milestone for the industrialization of sodium-ion batteries technology.

As CATL's first strategic partner for sodium-ion energy storage, HyperStrong will work closely with CATL in areas including technology R&D, product applications, and project deployment.

This partnership marks CATL's successful breakthrough across the entire value chain for mass production of sodium-ion batteries, giving the company the capacity for large-scale delivery. It also represents the largest sodium-ion battery supply agreement in the world to date, ushering in a new phase of large-scale expansion for the global sodium-ion battery industry.

Through morphology control and surface modification, CATL has significantly enhanced the energy density of sodium-ion batteries. On the manufacturing side, the Company has systematically addressed key process challenges in mass production—such as foaming in hard carbon production lines and moisture control—by leveraging core technologies including angstrom-level pore size regulation, surface molecular water-locking, and adaptive dynamic formation, thereby ensuring consistency across large-volume production.

Sodium-ion batteries offer excellent adaptability across a wide temperature range, deliver outstanding high-temperature cycle life, generate less heat during operation, and experience lower cell expansion stress, resulting in superior safety and stability. In long-duration energy storage applications, system integration can be effectively simplified, reducing auxiliary energy losses and comprehensively improving overall plant efficiency and economic performance.

In addition, CATL's sodium-ion energy storage batteries feature a platform-based design with the same form factor as lithium-ion batteries, ensuring high compatibility with the existing industrial chain. This effectively reduce adaptation costs and significantly shortens the timeline from product readiness to power station deployment.

The 60GWh sodium-ion battery cooperation marks a major milestone for both parties. As sodium-ion technology enters a phase of large-scale development, the two sides will continue to deepen collaboration, promote high-quality growth of the energy storage industry, and provide more resilient and diversified technological support for the global energy transition.